Aptar Pharma acquires Metaphase Design Group

Acquisition helps Aptar Pharma to be a single source provider to its pharmaceutical and biotech customers

125
Aptar Pharma acquires Metaphase Design Group, Inc.
Aptar Pharma has acquired Metaphase Design Group.

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announced that it has acquired Metaphase Design Group, a leader in applying the science of human factors engineering and ergonomics to product design.

The acquisition expands Aptar Pharma’s portfolio of services as well as the business’s ability to become a single source provider to its pharmaceutical and biotech customers throughout its drug development journey. The transaction enhances Aptar Pharma’s ability to transform ideas into user-centric solutions by capturing the voice of the patient every step of the way, from formulation to device design capabilities, and bringing best-in-class drug delivery solutions to the market.

Founded in 1991, Metaphase incorporates various areas of specialization in its user-centered design innovation process, combining them with extensive expertise in industrial design and human factors research and support. These include formative and summative studies, threshold analysis, patient journey mapping, risk analysis, regulatory submission support, and UX design to help their clients optimize their product development journey.

Metaphase will be integrated into Noble, an Aptar Pharma company and a world leader in drug delivery training device programs, medical device training solutions, market insight services, and patient onboarding strategies. The addition of Metaphase to Noble enhances Aptar Pharma’s patient-centric approach.

Metaphase’s expertise will also complement the products and services that Noble currently provides to pharmaceutical and biotech companies to help improve patient training and onboarding, including their human factors plus (HF+) program. Launched in 2021, Noble’s HF+ program offers its clients an expansive platform of services, including device selection, product design solutions, human factors testing, risk analysis, packaging and labeling services, and regulatory submission support.

Gael Touya, President of Aptar Pharma, said, “We are pleased to welcome Metaphase to the Aptar Pharma family. The combined expertise of Noble and Metaphase in human factors fully aligns with our mission to bring the voice of the patient into all parts of the development process. At Aptar Pharma, our primary goal is improving patients’ experiences and health outcomes.”

We are excited to be joining Aptar Pharma and to expand our ability to impact the pharmaceutical industry and help our clients optimize the design of their devices while continuing to serve our loyal client base in healthcare, consumer, and food and beverage markets,” Dr Bryce Rutter, Metaphase Design Group CEO, said. “Combining our resources with the foundation that Noble has established with their human factors plus program, will better enable us to represent the voice of the user throughout the product development journey.”

Craig Baker, vice-president of commercialization at Noble added, “With Metaphase’s work in design and expertise in ergonomics, this acquisition fully complements our work here at Noble in building a better patient experience through innovative training solutions and strategies inspired by listening to patients themselves.”

Founded in 1991, Metaphase Design Group is a leading expert in ergonomic product design and a specialist in the design of high-touch hand-intensive products and packaging. Working with several of the world’s largest and most prestigious brands across multiple industries, 

Metaphase combines decades of research, human factors, and industrial design experience with expertise in user insights, hand function, ergonomics, design ideation and development, and social sciences to develop and implement realistic design solutions that enable brands to patent designs, optimize product performance and to help improve the overall user experience.  

Aptar Pharma is part of AptarGroup, Inc., a leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing, and active material science solutions and services. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home care, food, and beverage.

The Covid-19 pandemic led to the country-wide lockdown on 25 March 2020. It will be two years tomorrow as I write this. What have we learned in this time? Maybe the meaning of resilience since small companies like us have had to rely on our resources and the forbearance of our employees as we have struggled to produce our trade platforms.

The print and packaging industries have been fortunate, although the commercial printing industry is still to recover. We have learned more about the digital transformation that affects commercial printing and packaging. Ultimately digital will help print grow in a country where we are still far behind in our paper and print consumption and where digital is a leapfrog technology that will only increase the demand for print in the foreseeable future.

Web analytics show that we now have readership in North America and Europe amongst the 90 countries where our five platforms reach. Our traffic which more than doubled in 2020, has at times gone up by another 50% in 2021. And advertising which had fallen to pieces in 2020 and 2021, has started its return since January 2022.

As the economy approaches real growth with unevenness and shortages a given, we are looking forward to the PrintPack India exhibition in Greater Noida. We are again appointed to produce the Show Daily on all five days of the show from 26 to 30 May 2022.

It is the right time to support our high-impact reporting and authoritative and technical information with some of the best correspondents in the industry. Readers can power Packaging South Asia’s balanced industry journalism and help sustain us by subscribing.

– Naresh Khanna

Subscribe Now

LEAVE A REPLY

Please enter your comment!
Please enter your name here